Cargando…
Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
The advent of stem cell-derived cerebral organoids has already advanced our understanding of disease mechanisms in neurological diseases. Despite this, many remain without effective treatments, resulting in significant personal and societal health burden. Antisense oligonucleotides (ASOs) are one of...
Autores principales: | Lange, Jenny, Zhou, Haiyan, McTague, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274522/ https://www.ncbi.nlm.nih.gov/pubmed/35836547 http://dx.doi.org/10.3389/fnmol.2022.941528 |
Ejemplares similares
-
Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020) -
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
por: Hammond, Suzan M, et al.
Publicado: (2021) -
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021) -
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017) -
Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)